MREO - Mereo BioPharma Group plc

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Show:
Income statement
Balance sheet
Annual

Cash flow

Currency in GBP. All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Cash flows from operating activities
Net income
-34,196
-34,196
12,725
-163,628
-34,844
Depreciation & amortisation
727
727
642
1,599
1,577
Stock-based compensation
3,862
3,862
3,302
1,558
1,636
Change in working capital
1,821
1,821
-1,845
-3,410
-7,666
Other working capital
-38,830
-38,830
-5,774
-28,357
-45,952
Other non-cash items
2,050
2,050
13,409
5,225
-429
Net cash provided by operating activities
-38,820
-38,820
-5,239
-28,341
-45,931
Cash flows from investing activities
Investments in property, plant and equipment
-10
-10
-535
-16
-21
Acquisitions, net
0
0
0
-354
-
Sales/maturities of investments
-
-
0
0
32,865
Other investing activities
-673
-673
-
-
-
Net cash used for investing activities
1,497
1,497
-421
1,495
43,295
Cash flows from financing activities
Debt repayment
-937
-937
-692
-21,888
-2,212
Common stock issued
0
0
78,532
20,136
0
Common stock repurchased
-
-
0
0
-998
Dividends paid
0
0
0
0
0
Other financing activities
153
153
-234
-4,986
-761
Net cash used provided by (used for) financing activities
-784
-784
77,652
34,737
-5,710
Net change in cash
-38,107
-38,107
71,992
7,891
-8,346
Cash at beginning of period
94,296
94,296
23,469
16,347
25,042
Cash at end of period
56,334
56,334
94,296
23,469
16,347
Free cash flow
Operating cash flow
-38,820
-38,820
-5,239
-28,341
-45,931
Capital expenditure
-10
-10
-535
-16
-21
Free cash flow
-38,830
-38,830
-5,774
-28,357
-45,952